Kodiak Sciences Inc. Kodiak Sciences Inc.

Kodiak Sciences Inc.

KOD

Helyezés a részvények között #3241
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Részvényárfolyam
$86.45
Piaci kapitalizáció
$5.43B
Változás (1 nap)
-1.45%
Változás (1 év)
378.92%
Ország
US
Kereskedés Kodiak Sciences Inc. (KOD)

Kategória

Healthcare
Kodiak Sciences Inc. (KOD) részvényárfolyamának története
Legmagasabb napi záróár: $91.79 ekkor: 2026-10-01

Legalacsonyabb napi záróár: $1.97 ekkor: 2018-10-01
Kodiak Sciences Inc. részvényárfolyamának története 2018 és 2026 között
Éves részvényárfolyam teljesítmény
Év Teljesítmény
2026 (TTM) 40.97%
2025 191.32%
2024 200.90%
2023 -58.27%
2022 -59.80%
2021 -36.18%
2020 106.84%
2019 776.39%
2018 0.00%
Hasonló cégek vagy versenytársak részvényárai
Vállalat Részvényár Változás 1év% Ország
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $536.74 25.87%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $227.23 746.28%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $137.83 -3.78%
AU
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $291.76 2.51%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $881.75 8.30%
NL